Renal Cell Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Conditions: Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Renal Cell Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Conditions: Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Renal Cell Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Conditions: Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Renal Cell Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Conditions: Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Renal Cell Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma Interventions: Drug: sunitinib or pazopanib; Drug: PD-1 inhibitor combined with axitinib Sponsors: RenJi Hospital; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; West China Hospital; Xiangya Hospital of Central South University; Fudan University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Second Aff iliated Hospital of Nantong University; Peking University First Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; ...
Source: ClinicalTrials.gov - April 18, 2023 Category: Research Source Type: clinical trials
